← All candidates
79 insider filings on record.
79 filings on record.
APLSApellis Pharmaceuticals, Inc.
—
$41.03
+0.00% · May 15
79 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · dailyNo open-market activity in range
▸ hover a marker for the filing · drag to zoom
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Short % float
Pro
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
74 more transactions on Pro →Context
Wall St
$40.92 avg target
-0.3% vs today · 13 analysts · consensus Hold
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
3 of 4 quarters beat
Q1 '26$0.15 act+$0.51
Q4 '25−$0.47 act−$0.08
Q3 '25$1.67 act+$0.73
Q2 '25−$0.33 act+$0.14
Coverage
Biogen’s Apellis Deal And Alzheimer’s Trial Shift Focus Beyond PriceSimply Wall St. · 05-18Biogen completes $5.3B Apellis Pharmaceuticals acquisitionQuartz · 05-15Compared to Estimates, Apellis Pharmaceuticals (APLS) Q1 Earnings: A Look at Key MetricsZacks · 05-07Apellis Pharmaceuticals, Inc. (APLS) Tops Q1 Earnings and Revenue EstimatesZacks · 05-07
The file stays open
79 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice